ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2025

Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes.

Pier Luigi TemporelliPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.